PUBLISHER: The Business Research Company | PRODUCT CODE: 1889484
PUBLISHER: The Business Research Company | PRODUCT CODE: 1889484
An implantable glucose sensor is a small medical device placed beneath the skin to continuously measure the body's glucose levels and transmit the readings to an external monitor or smart device. It helps individuals manage diabetes more easily by offering real-time data without the need for frequent finger-prick tests. The device functions inside the body for an extended duration, providing a more convenient and consistent method for monitoring blood sugar.
The key product types of implantable glucose sensors include long-term implantable sensors and short-term implantable sensors. Long-term implantable sensors are glucose monitoring devices designed to remain under the skin for an extended period-typically weeks to months-to continuously measure blood glucose levels. These sensors utilize technologies such as enzymatic and non-enzymatic methods and are used for conditions such as type 1 diabetes, type 2 diabetes, and gestational diabetes. They serve end users including hospitals, clinics, home-care settings, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.
The implantable glucose sensor market research report is one of a series of new reports from The Business Research Company that provides implantable glucose sensor market statistics, including implantable glucose sensor industry global market size, regional shares, competitors with a implantable glucose sensor market share, detailed implantable glucose sensor market segments, market trends and opportunities, and any further data you may need to thrive in the implantable glucose sensor industry. This implantable glucose sensor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The implantable glucose sensor market size has grown rapidly in recent years. It will grow from $7.09 billion in 2024 to $8.14 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. Growth in the historic period can be attributed to the increasing prevalence of diabetes, rising demand for continuous glucose monitoring, growing patient awareness of diabetes complications, expanding healthcare infrastructure, and improving reimbursement policies.
The implantable glucose sensor market size is expected to see rapid growth in the next few years. It will grow to $14.03 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. Growth in the forecast period can be linked to the rising incidence of diabetes, growing demand for minimally invasive glucose sensors, expanded integration of digital health technologies, increased use of subscription-based business models, expansion into emerging markets, and rising regulatory support. Major trends expected during the forecast period include technological advancements in sensor longevity, development of biocompatible materials, innovations in wireless connectivity, improved calibration accuracy, and ongoing research and development in implantable architectures.
The rising prevalence of diabetes is expected to drive the growth of the implantable glucose sensor market in the coming years. Diabetes is a chronic condition in which the body cannot properly regulate blood sugar or glucose levels. Its prevalence is increasing largely due to unhealthy lifestyle habits, such as reduced physical activity and higher consumption of calorie-dense foods, which raise the risk of developing type 2 diabetes. Implantable glucose sensors support diabetes management by providing continuous, long-term monitoring of blood glucose levels, making them especially useful for patients who require tight glucose control. By offering real-time data and alerts, these devices reduce the need for frequent finger-prick tests, enhancing patient convenience and improving overall health outcomes. For example, according to the UK's National Health Service, in 2023, 3,615,330 individuals registered with a general practitioner were diagnosed with non-diabetic hyperglycemia or pre-diabetes, representing an 18% increase from 3,065,825 cases in 2022. As a result, the growing prevalence of diabetes is fueling the expansion of the implantable glucose sensor market.
Major players in the implantable glucose sensor market are focusing on developing advanced devices, such as long-term implantable sensors, to improve patient convenience, health outcomes, and reduce the need for frequent device management. Long-term implantable sensors are medical devices placed under the skin to continuously measure glucose levels in the interstitial fluid over extended periods, unlike short-term sensors that require frequent replacement. For instance, in September 2024, Senseonics Holdings Inc., a US-based medical technology company, received FDA approval for the Eversense 365 continuous glucose monitoring system for individuals aged 18 and older with Type 1 or Type 2 diabetes. The system features a fully implantable sensor that lasts up to 365 days, providing continuous glucose readings and alerts for high and low glucose levels. It also connects to a mobile app and cloud platform, allowing patients and healthcare providers to remotely monitor glucose trends and make informed treatment decisions.
In May 2024, Senseonics Holdings Inc. partnered with Mercy to expand the clinical adoption of the Eversense continuous glucose monitoring system across Mercy's network. This collaboration enables patients to benefit from long-duration implantable glucose monitoring, supported by remote patient monitoring and streamlined endocrinology workflows. Mercy is a US-based integrated healthcare organization offering hospital care, outpatient services, virtual care, and chronic disease management programs.
Major companies operating in the implantable glucose sensor market are Cirtec Medical Corporation, Biolinq Inc., Senseonics Holdings Inc., Biorasis Inc., GlucoTrack Inc., GluSense Ltd., GlucoTech Ltd., Integrated Medical Sensors Inc., World Precision Instruments, Indigo Diabetes N.V., GlySens Incorporated, Profusa Inc., Lifecare ASA
North America was the largest region in the implantable glucose sensor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in implantable glucose sensor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the implantable glucose sensor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The implantable glucose sensor market consists of sales of implantable glucose monitoring devices, biocompatible sensor probes, external data transmitters, wearable reader units, calibration accessories, and adhesive patches. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Implantable Glucose Sensor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on implantable glucose sensor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for implantable glucose sensor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The implantable glucose sensor market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.